BR112016013572A2 - - Google Patents
Info
- Publication number
- BR112016013572A2 BR112016013572A2 BR112016013572A BR112016013572A BR112016013572A2 BR 112016013572 A2 BR112016013572 A2 BR 112016013572A2 BR 112016013572 A BR112016013572 A BR 112016013572A BR 112016013572 A BR112016013572 A BR 112016013572A BR 112016013572 A2 BR112016013572 A2 BR 112016013572A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013267687 | 2013-12-25 | ||
| JP2013-267687 | 2013-12-25 | ||
| PCT/JP2014/083932 WO2015098853A1 (ja) | 2013-12-25 | 2014-12-22 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016013572A2 true BR112016013572A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2017-10-03 |
| BR112016013572B1 BR112016013572B1 (pt) | 2023-03-21 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013572-5A BR112016013572B1 (pt) | 2013-12-25 | 2014-12-22 | Composto (6s,9as)-n-benzil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3- (piperazina-1-il)azetidina-1-il]piridina-2-il}metil)-2-(prop-2-en-1-il)-octaidro-1hpirazino[2,1-c][1,2,4]triazina-1-carboxamida |
Country Status (34)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| EP3263106B1 (en) | 2015-02-25 | 2023-10-25 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CA2988707C (en) * | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| RU2723551C2 (ru) * | 2015-06-23 | 2020-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида |
| MX381976B (es) | 2015-08-20 | 2025-03-13 | Eisai R&D Man Co Ltd | Agente terapéutico contra tumores. |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| BR112019014127A2 (pt) * | 2017-02-08 | 2020-02-11 | Eisai R&D Management Co., Ltd. | Composição farmacêutica para tratamento de tumores |
| SG11201910100PA (en) | 2017-05-16 | 2019-11-28 | Eisai R&D Man Co Ltd | Treatment of hepatocellular carcinoma |
| EP4051278A1 (en) | 2019-10-29 | 2022-09-07 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| IL296257B2 (en) | 2020-03-12 | 2025-06-01 | 3 2 Pharma Llc | (6S,9aS)-8-ARYL-6-OXYBENZYL-4,7-DIOXO-2-(HETEROARYL)HEXAHYDRO-2H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1(6H)-CARBOXAMIDES AS CBP/BETA-CATENIN ANTAGONISTS |
| JPWO2022092294A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2020-10-30 | 2022-05-05 | ||
| US20240352020A1 (en) * | 2021-08-26 | 2024-10-24 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| MX2024002060A (es) * | 2021-09-08 | 2024-03-01 | Eisai R&D Man Co Ltd | Composicion farmaceutica para tratar tumores solidos. |
| CN116262120A (zh) * | 2021-12-13 | 2023-06-16 | 上海中医药大学 | 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| CN118785911A (zh) | 2022-03-31 | 2024-10-15 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60227093D1 (de) * | 2001-10-12 | 2008-07-24 | Choongwae Pharma Corp | Reverse-turn-mimetika und diese betreffendes verfahren |
| US8080657B2 (en) * | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| EP2650295A1 (en) | 2008-06-06 | 2013-10-16 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| US20100267672A1 (en) * | 2009-04-15 | 2010-10-21 | Choongwae Pharma Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| CN103209982B (zh) * | 2010-10-14 | 2016-03-16 | Jw制药公司 | 反转模拟物的化合物、其制造方法及其用途 |
| EP2678341A1 (en) * | 2011-02-25 | 2014-01-01 | PRISM Pharma Co., Ltd. | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 SM SM20190306T patent/SMT201900306T1/it unknown
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active Active
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja active Application Filing
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
-
2019
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09Y | Publication of grant cancelled [chapter 9.1.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2705 DE 08/11/2022 POR TER SIDO INDEVIDA. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2014, OBSERVADAS AS CONDICOES LEGAIS |